A

Aytu BioPharma
D

AYTU

1.48000
USD
-0.01
(-0.67%)
Market Closed
Volume
29
EPS
-2
Div Yield
-
P/E
-1
Market Cap
8,839,044
Related Instruments
    A
    APT
    0.07000
    (1.34%)
    5.30000 USD
    C
    CODX
    -0.04000
    (-3.64%)
    1.06000 USD
    I
    INO
    -0.54000
    (-11.25%)
    4.26000 USD
    MRNA
    MRNA
    -2.950
    (-7.42%)
    36.830 USD
    O
    OPK
    0.01500
    (0.92%)
    1.64500 USD
    More
News

Title: Aytu BioPharma

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complimentary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidityand a significantly shortened lifespan. AR101/enzastaurin has received Orphan Drug designation from the FDA. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which it generates maximum revenue from the Rx segment.